Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry

Sponsor
Reichert, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT04360369
Collaborator
(none)
61
1
3
6.3
9.7

Study Details

Study Description

Brief Summary

Determine if the Tono-Vera Tonometer accurately measures intraocular pressure (IOP). The hypothesis of this test is to confirm the Tono-Vera Tonometer is equivalent to the Goldmann Applanation Tonometer (within +/- 5.0 mmHg).

Condition or Disease Intervention/Treatment Phase
  • Device: IOP with Goldmann Applanation Tonometer
  • Device: IOP with comparator ORA G3 and ic100 tonometers
  • Device: IOP with Tono-Vera Tonometer
N/A

Detailed Description

The Tono-Vera Tonometer (Reichert, Inc.) is a portable rebound tonometer intended to measure IOP. Subjects will undergo a standard ophthalmologic examination. Subjects will then be measured with four tonometers: Goldmann Applanation Tonometer (C.S.O. SRL), Ocular Response Analyzer G3 (Reichert, Inc.), iCare ic100 tonometer (iCare Finland Oy), and Tono-Vera Tonometer.

Study Design

Study Type:
Interventional
Actual Enrollment :
61 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
All study-related tests will be conducted in a single stage, with one clinical visit, to a single clinical center.All study-related tests will be conducted in a single stage, with one clinical visit, to a single clinical center.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Comparison of Intraocular Pressure Measurements Between Reichert Tono-Vera Tonometer and Goldmann Tonometry
Actual Study Start Date :
Oct 19, 2020
Actual Primary Completion Date :
Apr 28, 2021
Actual Study Completion Date :
Apr 28, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Goldmann Applanation Tonometer

Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.

Device: IOP with Goldmann Applanation Tonometer
Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (>23 mmHg).

Active Comparator: ORA G3 and ic100

Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.

Device: IOP with comparator ORA G3 and ic100 tonometers
Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.

Experimental: Tono-Vera Tonometer

Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.

Device: IOP with Tono-Vera Tonometer
Measurement of IOP with Tono-Vera Tonometer

Outcome Measures

Primary Outcome Measures

  1. Demonstrate compliance with ANSI Z80.10-2014-Ophthalmics-Ophthalmic Instruments-Tonometers. [Through study completion, approximately 4 months.]

    Subjects will be distributed into Low IOP, Medium IOP, and High IOP groups based on Goldmann Applanation Tonometer measurements. The Tono-Vera Tonometer measurements will be within +/-5.0 mmHg of the Goldmann Applanation Tonometer measurements in all groups.

Secondary Outcome Measures

  1. Data collection for two measurement modes. [Through study completion, approximately 4 months.]

    Tono-Vera has two measurement modes: A 6-measurement mode & "Quick" measurement mode. The 6-measurement mode will be used during this study. It will be possible to post-process the results to determine the IOP value that would have been obtained using Quick mode. As such the sponsor will be able to ensure the accuracy of both measurement modes compared to Goldmann Tonometry.

  2. Data collection for device calibration. [Through study completion, approximately 4 months.]

    The study will collect data on a large number of patients over a wide range of IOP values. The sponsor may use the collected data in a post-hoc analysis to verify that the Tono-Vera Tonometer factory calibration is optimal.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects must be male or female, between the ages of 18 and 90 years old;

  • Be able and willing to provide signed informed consent

  • Be able to follow study instructions

Exclusion Criteria:
  • Subjects with only one functional eye;

  • Subjects with one eye having poor or eccentric fixation;

  • Subjects with central corneal thickness greater than 600 µm or less than 500 µm (about 2 standard deviations the human mean);

  • Subjects with corneal scarring or who have had corneal surgery, including corneal laser surgery;

  • Subjects with concomitant ocular diseases such as: microphthalmos, buphthalmos, nystagmus, keratoconus, severe dry eye syndrome, blepharospasm, any other corneal or conjunctival pathology or infection;

  • Contact lens wearers;

  • Known allergy to proparacaine or fluorescein as these are used to anesthetize the eye and allow IOP measurement, respectively, when used with the GAT.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Ophthalmology, Duke University Durham North Carolina United States 27705

Sponsors and Collaborators

  • Reichert, Inc.

Investigators

  • Principal Investigator: Henry Tseng, MD, PhD, Department of Opthalmology, Duke University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Reichert, Inc.
ClinicalTrials.gov Identifier:
NCT04360369
Other Study ID Numbers:
  • 16305-TPR-28
First Posted:
Apr 24, 2020
Last Update Posted:
Jan 3, 2022
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Reichert, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 3, 2022